Hanson Pharmaceuticals (03692) reversed the market and rose by more than 5%. As of press release, it rose 4.65% to HK$15.74, with a turnover of HK$40,882,900.
The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) reversed the market and rose by more than 5%. As of press release, it had risen 4.65% to HK$15.74, with a turnover of HK$40,882,900.
According to the news, Hanson Pharmaceuticals announced that it has signed a licensing agreement with Promise Biotechnology (Zhuhai). Based on this, the company obtained an exclusive license to use HS-20117 for the development, production and commercialization of bispecific antibody conjugate products worldwide, and has the right to further sub-license. HS-20117 inhibits tumor growth and survival by specifically targeting tumor antigens EGFR and cMet, and is currently in phase I clinical research.
According to the announcement, the company will make down payments and potential payments for ADC-based product development, registration and commercialization milestones based on sales totaling no more than RMB 5 billion, as well as tiered royalties based on global net sales.